Jasper Smit, Frank J Borm, Nienke R Gerards, Sanne E Wiegers, Daniel Holden, David Leung, Diederik J Grootendorst, Bert Windhorst, Nabeel Nabulsi, Zhengxin Cai, Yiyun Huang, Richard E Carson, Scott Gettinger, Egbert F Smit, Ronald Boellaard, Adrianus J de Langen
{"title":"PD-L1 PET/CT imaging with <sup>18</sup>F-BMS-986,229 and <sup>18</sup>F-BMS-986,192 in patients with advanced-stage non-small cell lung cancer.","authors":"Jasper Smit, Frank J Borm, Nienke R Gerards, Sanne E Wiegers, Daniel Holden, David Leung, Diederik J Grootendorst, Bert Windhorst, Nabeel Nabulsi, Zhengxin Cai, Yiyun Huang, Richard E Carson, Scott Gettinger, Egbert F Smit, Ronald Boellaard, Adrianus J de Langen","doi":"10.1007/s00259-026-08188-4","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Predicting response to checkpoint inhibitors in non-small cell lung cancer (NSCLC) remains challenging. In addition to programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC), PD-L1 imaging could improve response prediction. This study evaluated a novel PD-L1 PET tracer, <sup>18</sup>F-BMS-986,229, and compared its performance to <sup>18</sup>F-BMS-986,192, which shares the same target.</p><p><strong>Methods: </strong>Stage IV NSCLC patients were scheduled for baseline PET/CT scans with both tracers. Tracer uptake was quantified using SUVpeak and SUVmean. Imaging findings were correlated with PD-L1 expression from tumor biopsies and clinical outcomes, including best overall response and overall survival.</p><p><strong>Results: </strong><sup>18</sup>F-BMS-986,192 and <sup>18</sup>F-BMS-986,229 performed equally with respect to tumor tracer uptake. Mean SUVpeak was 2.75 (SD 1.53) vs. 2.68 (SD 1.78), p = 0.780. Tumor tracer uptake did not correlate with PD-L1 IHC, mean SUVpeak in the PD-L1 tps < 50% group was 3.77 vs. 3.54 in the PD-L1 ≥ 50% group (p = 0.8175). Explorative analysis of the association between tumor tracer uptake and OS revealed that a low SUVpeak excluded a long OS, whereas a higher SUVpeak did not discriminate between patients with a short or long OS.</p><p><strong>Conclusion: </strong><sup>18</sup>F-BMS-986,229 and <sup>18</sup>F-BMS-986,192 performed equally with respect to tumor uptake. In this small cohort, baseline PD-L1 tracer uptake did not correlate with PD-L1 IHC. Low tumor tracer uptake may be associated with shorter overall survival, warranting further investigation.</p><p><strong>Clinical trial registration: </strong>NCT03001882, https//clinicaltrials.gov/study/NCT03001882.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":""},"PeriodicalIF":7.6000,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Nuclear Medicine and Molecular Imaging","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00259-026-08188-4","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: Predicting response to checkpoint inhibitors in non-small cell lung cancer (NSCLC) remains challenging. In addition to programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC), PD-L1 imaging could improve response prediction. This study evaluated a novel PD-L1 PET tracer, 18F-BMS-986,229, and compared its performance to 18F-BMS-986,192, which shares the same target.
Methods: Stage IV NSCLC patients were scheduled for baseline PET/CT scans with both tracers. Tracer uptake was quantified using SUVpeak and SUVmean. Imaging findings were correlated with PD-L1 expression from tumor biopsies and clinical outcomes, including best overall response and overall survival.
Results: 18F-BMS-986,192 and 18F-BMS-986,229 performed equally with respect to tumor tracer uptake. Mean SUVpeak was 2.75 (SD 1.53) vs. 2.68 (SD 1.78), p = 0.780. Tumor tracer uptake did not correlate with PD-L1 IHC, mean SUVpeak in the PD-L1 tps < 50% group was 3.77 vs. 3.54 in the PD-L1 ≥ 50% group (p = 0.8175). Explorative analysis of the association between tumor tracer uptake and OS revealed that a low SUVpeak excluded a long OS, whereas a higher SUVpeak did not discriminate between patients with a short or long OS.
Conclusion: 18F-BMS-986,229 and 18F-BMS-986,192 performed equally with respect to tumor uptake. In this small cohort, baseline PD-L1 tracer uptake did not correlate with PD-L1 IHC. Low tumor tracer uptake may be associated with shorter overall survival, warranting further investigation.
期刊介绍：
The European Journal of Nuclear Medicine and Molecular Imaging serves as a platform for the exchange of clinical and scientific information within nuclear medicine and related professions. It welcomes international submissions from professionals involved in the functional, metabolic, and molecular investigation of diseases. The journal's coverage spans physics, dosimetry, radiation biology, radiochemistry, and pharmacy, providing high-quality peer review by experts in the field. Known for highly cited and downloaded articles, it ensures global visibility for research work and is part of the EJNMMI journal family.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
